{"id":16002,"date":"2025-09-24T02:16:45","date_gmt":"2025-09-24T02:16:45","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/diet\/manjaro-glp1-sakyou-sa-en\/"},"modified":"2026-11-17T07:27:14","modified_gmt":"2026-11-17T07:27:14","slug":"manjaro-glp1-sakyou-sa-en","status":"publish","type":"post","link":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/","title":{"rendered":"How Mounjaro works | A doctor explains its dual action on GIP and GLP-1"},"content":{"rendered":"\n<style>\n.cv2-body .cv2-cards--hd .cv2-card{padding:0;overflow:hidden}\n.cv2-body .cv2-cards--hd .cv2-card__h{background:var(--c-cream);padding:12px 18px!important;margin:0!important;border-bottom:1px solid var(--c-line);font-weight:700}\n.cv2-body .cv2-cards--hd .cv2-card>p:not(.cv2-card__h){padding-left:18px!important;padding-right:18px!important;margin:0!important}\n.cv2-body .cv2-cards--hd .cv2-card__h+p{padding-top:12px!important}\n.cv2-body .cv2-cards--hd .cv2-card>p:last-child{padding-bottom:14px!important}\n.cv2-body .cv2-cards--hd .cv2-card>p.cv2-card__sup{margin:12px 14px 14px!important;padding:10px 12px!important;background:#fdf6e6;border-radius:8px;font-size:.85rem;line-height:1.8}\n.cv2-body h3.cv2-h3--num::before{display:none!important}\n.cv2-dg{margin:22px 0 26px;border:1px solid var(--c-line);border-radius:14px;overflow:hidden;background:var(--c-cream)}\n.cv2-body .cv2-dg__t{margin:0!important;background:var(--c-brown);color:#fff;text-align:center;font-weight:700;padding:12px 16px;font-size:1rem;font-family:var(--f-sans)}\n.cv2-dg__g{list-style:none!important;margin:0!important;padding:16px!important;display:grid;grid-template-columns:repeat(3,minmax(0,1fr));gap:12px}\n.cv2-dg__g>li{background:#fff;border:1px solid var(--c-line);border-radius:12px;padding:16px 12px!important;text-align:center;margin:0!important;display:block}\n.cv2-dg__n{display:inline-flex;width:30px;height:30px;border-radius:50%;background:var(--c-brown);color:#fff;font-weight:700;align-items:center;justify-content:center;font-size:.9rem;margin-bottom:6px;font-family:var(--f-sans)}\n.cv2-body .cv2-dg__h{font-weight:700;color:var(--c-brown-d);font-size:1.05rem;margin:0 0 6px!important;font-family:var(--f-sans)}\n.cv2-body .cv2-dg__i{margin:0!important;font-size:.88rem;line-height:1.7}\n.cv2-body .cv2-dg__f{margin:0!important;text-align:center;font-size:.8rem;color:var(--c-mut);padding:0 12px 14px}\n.cv2-dg--bad .cv2-dg__i::before{content:\"\\\\00d7\";color:#b53a3a;font-weight:700;margin-right:6px}\n.cv2-dg--ok .cv2-dg__i::before{content:\"\\\\2713\";color:var(--c-brown);font-weight:700;margin-right:6px}\n.cv2-sc{list-style:none!important;margin:18px 0 22px!important;padding:0!important;display:grid;grid-template-columns:repeat(3,minmax(0,1fr));gap:12px;counter-reset:cv2sc}\n.cv2-sc--2{grid-template-columns:repeat(2,minmax(0,1fr))}\n.cv2-sc>li{counter-increment:cv2sc;position:relative;background:#fff;border:1px solid var(--c-line);border-radius:14px;padding:16px 18px 16px 64px!important;margin:0!important;font-size:.9rem;line-height:1.8}\n.cv2-sc>li::before{content:counter(cv2sc);position:absolute;left:16px;top:14px;width:32px;height:32px;border-radius:50%;background:var(--c-brown);color:#fff;font-weight:700;display:flex;align-items:center;justify-content:center;font-family:var(--f-sans)}\n.cv2-body .cv2-sc__h{font-weight:700;color:var(--c-brown-d);margin:0 0 4px!important;font-size:1rem;line-height:1.5;font-family:var(--f-sans)}\n.cv2-body .cv2-sc p{margin:0!important;font-size:.88rem}\n.cv2-li__l{display:block;font-weight:700;color:#a04e10}\n.cv2-caution li{padding-left:18px}\n@media(max-width:767px){\n.cv2-dg__g,.cv2-sc,.cv2-sc--2{grid-template-columns:1fr}\n.cv2-dg__g>li{display:flex;gap:12px;text-align:left;align-items:flex-start;padding:14px!important}\n.cv2-dg__n{flex:0 0 30px;margin:0}\n}\n\n.cv2-body ul.cv2-ul--frame{margin:14px 0 18px!important;padding:14px 18px 10px 20px!important;border:1px solid var(--c-line);border-radius:12px;background:#fff}\n.cv2-tablewrap{margin:22px 0;overflow-x:auto;-webkit-overflow-scrolling:touch;border:1px solid var(--c-line);border-radius:12px}\n.cv2-tablewrap .wp-block-table,.cv2-tablewrap figure{margin:0!important}\n.cv2-tablewrap table{width:100%;min-width:560px;border-collapse:collapse;font-size:.88rem;line-height:1.7;border:none;margin:0}\n.cv2-tablewrap th{background:var(--c-brown);color:#fff;font-weight:700;padding:11px 14px;text-align:left;border:none!important}\n.cv2-tablewrap td{padding:12px 14px;border:none!important;border-top:1px solid var(--c-line)!important;vertical-align:top;background:#fff}\n.cv2-tablewrap td:first-child{background:var(--c-cream);font-weight:700;width:26%;position:sticky;left:0}\n.cv2-tablewrap tbody tr.is-urgent>td{background:#fdeeee}.cv2-tablewrap tbody tr.is-urgent>td:first-child{background:#f9dada;color:#a32d2d}\n.cv2-body .cv2-cards--hd .cv2-card>ul{margin:0!important;padding:12px 18px 14px!important}\n@media(max-width:767px){.cv2-tablewrap::before{content:\"\u2190 Scroll sideways \u2192\";display:block;font-size:.7rem;color:var(--c-mut);text-align:right;padding:6px 10px 0;position:sticky;left:0}}\n.cv2-body .cv2-sc>li{display:grid;grid-template-columns:32px minmax(0,1fr);column-gap:12px;align-items:center;align-content:start;padding:16px 18px!important}\n.cv2-body .cv2-sc>li::before{position:static;grid-column:1;grid-row:1;flex:none}\n.cv2-body .cv2-sc>li>.cv2-sc__h{grid-column:2;grid-row:1;margin:0!important}\n.cv2-body .cv2-sc>li>p:not(.cv2-sc__h){grid-column:1\/-1;margin-top:10px!important}\n.cv2-body .cv2-card .cv2-ul:not([class*=\"cv2-ul--\"]) li{padding-left:0!important}\n.cv2-body .cv2-tablewrap .cv2-tablewrap{margin-top:0!important;margin-bottom:0!important;border:0!important;border-radius:0!important;overflow:visible}\n.cv2-body .cv2-tablewrap .cv2-tablewrap::before{display:none!important}\n<\/style>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mounjaro differs in its mechanism of action from existing GLP-1 receptor agonists in that it acts on two types of hormones, GIP and GLP-1, at the same time.<\/strong> In recent years, GLP-1 receptor agonists (GLP-1 RAs) have attracted attention as drug therapy for obesity and type 2 diabetes. Among them, <strong>Mounjaro<\/strong> has been reported to show a distinctive mechanism of action and clinical effects compared with other GLP-1 receptor agonists. This article summarizes and explains Mounjaro&#8217;s mechanism of action, its effects on weight loss and blood sugar improvement, how it differs from other GLP-1 receptor agonists, and the evidence from clinical trials.<\/p>\n\n\n\n<div class=\"cv2-conclusion\"><p class=\"cv2-conclusion__t\"><span>Key points first<\/span>Short on time? Just read this part<\/p><ul><li>Mounjaro is the first dual-acting injectable medication in Japan that binds to <strong>two receptors, GIP and GLP-1<\/strong><\/li><li>Mounjaro&#8217;s action is made up of <strong>four pathways<\/strong>: glucose-dependent stimulation of insulin secretion, suppression of glucagon, delayed gastric emptying, and appetite suppression<\/li><li>A key feature of Mounjaro is its high weight loss effect, owing to the addition of <strong>GIP action<\/strong><\/li><\/ul><\/div>\n\n\n\n<div class=\"what-you-learn-box\">\n<p><strong>What you will learn in this article<\/strong><\/p>\n<ul><li>How Mounjaro&#8217;s action differs from other GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide)<\/li><li>How Mounjaro acts on both GIP and GLP-1<\/li><li>Evidence from clinical trials on weight loss and blood sugar improvement<\/li><li>Points to keep in mind when choosing Mounjaro<\/li><\/ul>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>What are GLP-1 receptor agonists?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>GLP-1 receptor agonists are medications that mimic the action of a hormone that curbs the rise in blood sugar after meals, and they are involved in both improving blood sugar and suppressing appetite.<\/strong><\/mark> GLP-1 (glucagon-like peptide-1) is a hormone secreted from the intestine that helps regulate blood sugar after eating. GLP-1 lowers blood sugar through the following actions.<\/p>\n\n\n\n<ul class=\"cv2-ul cv2-ul--check cv2-ul--frame\"><li>Promoting insulin secretion from pancreatic beta cells (glucose-dependent)<\/li><li>Suppressing glucagon secretion from pancreatic alpha cells<\/li><li>Increasing the feeling of fullness by delaying gastric emptying<\/li><li>Acting on areas of the brain involved in appetite regulation<\/li><\/ul>\n\n\n\n<div class=\"cv2-point\"><p class=\"cv2-point__t\">Key point<\/p><p>Based on these actions, GLP-1 receptor agonists have been applied to the treatment of obesity and type 2 diabetes.<\/p><\/div>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>What is Mounjaro?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>Mounjaro is the first dual-acting injectable medication in Japan that binds to two receptors, GIP and GLP-1.<\/strong><\/mark> <strong>Mounjaro<\/strong> is a medication that acts on the receptors for both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, and it can be given as a once-weekly subcutaneous injection. In Japan it is approved as a medication for type 2 diabetes, and it is also attracting attention for its high weight loss effect.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The main features of Mounjaro are as follows.<\/p>\n\n\n\n<ol class=\"cv2-sc\"><li><p class=\"cv2-sc__h\">Dual GIP\/GLP-1 receptor agonist<\/p><p>Binds to two types of receptors and promotes insulin secretion in a glucose-dependent manner<\/p><\/li><li><p class=\"cv2-sc__h\">Appetite suppression<\/p><p>Clinical trials have reported that its appetite suppression and increase in fullness are stronger than with single GLP-1 drugs<\/p><\/li><li><p class=\"cv2-sc__h\">Long-acting<\/p><p>Maintains stable blood levels with once-weekly dosing<\/p><\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Mounjaro&#8217;s mechanism of action<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>Mounjaro&#8217;s action is made up of four pathways: glucose-dependent stimulation of insulin secretion, suppression of glucagon, delayed gastric emptying, and appetite suppression.<\/strong><\/mark> Like conventional GLP-1 receptor agonists, Mounjaro promotes glucose-dependent insulin secretion and suppresses glucagon. In addition, the major difference from other drugs is that <strong>by also acting on GIP receptors at the same time, it has been shown in clinical trials to have stronger appetite suppression and weight loss effects than GLP-1-only drugs<\/strong>.<\/p>\n\n\n\n<div class=\"cv2-cards cv2-cards--hd\"><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>3-1. Promoting insulin secretion and improving blood sugar<\/strong><\/p><p>Mounjaro binds to GLP-1 and GIP receptors on pancreatic beta cells and activates intracellular signaling pathways to increase insulin secretion. Because this is glucose-dependent, another advantage is a low risk of hypoglycemia when used alone.<\/p><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>3-2. Suppressing glucagon<\/strong><\/p><p>It acts on pancreatic alpha cells to suppress glucagon secretion, curbing glucose production (gluconeogenesis) in the liver and thereby limiting the rise in blood sugar.<\/p><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>3-3. Increased fullness through delayed gastric emptying<\/strong><\/p><p>By delaying gastric emptying, it curbs the rise in blood sugar after meals and keeps you feeling full for longer. This action is directly linked to appetite suppression and enhances the weight loss effect.<\/p><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>3-4. Action on areas of the brain involved in appetite regulation<\/strong><\/p><p>GLP-1 and GIP receptors are thought to also exist in areas of the brain involved in regulating appetite, such as the hypothalamus and the medulla oblongata. Mounjaro is thought to act on the appetite center through these receptors and <strong>reduce food intake<\/strong>. Clinical data such as the SURPASS-2 trial suggest that this central action is stronger than with GLP-1-only drugs, but the detailed mechanism is still being studied.<\/p><\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Differences from other GLP-1 receptor agonists<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>GLP-1 receptor agonists include liraglutide, semaglutide and dulaglutide, and Mounjaro is distinguished from these by whether or not it has GIP action.<\/strong><\/mark> The main differences compared with Mounjaro are as follows.<\/p>\n\n\n\n<div class=\"cv2-tablewrap\"><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Medication<\/th><th>Dosing frequency<\/th><th>Weight loss effect (clinical trials)<\/th><th>Features of action<\/th><th>Blood sugar improvement<\/th><\/tr><\/thead><tbody><tr><td>Mounjaro<\/td><td>Once weekly<\/td><td>About 15\u201321% (SURMOUNT-1)<\/td><td>Dual GIP + GLP-1 action<\/td><td>High<\/td><\/tr><tr><td>Liraglutide<\/td><td>Daily<\/td><td>About 5\u201310% (SCALE trial)<\/td><td>GLP-1 action only<\/td><td>High<\/td><\/tr><tr><td>Semaglutide<\/td><td>Once weekly<\/td><td>Around 15% (STEP 1 trial)<\/td><td>GLP-1 action only<\/td><td>High<\/td><\/tr><tr><td>Dulaglutide<\/td><td>Once weekly<\/td><td>A few percent (mainly focused on blood sugar improvement)<\/td><td>GLP-1 action only<\/td><td>High<\/td><\/tr><\/tbody><\/table><\/figure><\/div>\n\n\n\n<ul class=\"cv2-ul cv2-ul--check cv2-ul--frame\"><li><strong>A key feature of Mounjaro<\/strong> is its <strong>high weight loss effect<\/strong>, owing to the addition of GIP action.<\/li><li>Other drugs also have strong blood sugar\u2013improving effects, but they differ in the degree of appetite suppression and weight loss.<\/li><\/ul>\n\n\n\n<div class=\"cv2-midcta\"><p class=\"cv2-midcta__t\">Why not start by consulting online about the GLP-1 treatment that&#8217;s right for you?<\/p><div class=\"cv2-btns\"><a class=\"cv2-btn cv2-btn--coral\" href=\"https:\/\/mypage-online-reservation.hiro-clinic.or.jp\/register?department=diet\">Book a counseling session now<\/a><a class=\"cv2-btn cv2-btn--line\" href=\"https:\/\/www.hiro-clinic.or.jp\/diet\/line\/\">Free consultation on LINE<\/a><\/div><p class=\"cv2-midcta__d\" style=\"margin:12px 0 0!important\">*This is self-pay treatment. Effects and side effects vary from person to person.<\/p><\/div>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Mounjaro&#8217;s effects in clinical trials<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>Mounjaro&#8217;s effects have been verified in two series of trials: the SURMOUNT trials in patients with obesity and the SURPASS trials in patients with type 2 diabetes.<\/strong><\/mark> Many clinical trials of Mounjaro have been conducted in patients with obesity and patients with type 2 diabetes.<\/p>\n\n\n\n<div class=\"cv2-cards cv2-cards--hd cv2-cards--3\"><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>5-1. Weight loss effect<\/strong><\/p><ul class=\"cv2-ul\"><li>The SURMOUNT-1 trial (Jastreboff AM, <em>N Engl J Med<\/em>, 2022;387:205-216) reported <strong>an average weight loss of 7\u201321%<\/strong> after 72 weeks of treatment, depending on dose (15.0% in the 5 mg group, 19.5% in the 10 mg group, 20.9% in the 15 mg group, and 3.1% in the placebo group)<\/li><li>Shows a significant weight loss effect even in patients with obesity with a BMI of 30 or more<\/li><li>The effect is further enhanced when combined with dietary management and exercise therapy<\/li><\/ul><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>5-2. Blood sugar improvement effect<\/strong><\/p><ul class=\"cv2-ul\"><li>The SURPASS-2 trial (Fr\u00edas JP, <em>N Engl J Med<\/em>, 2021;385:503-515) reported HbA1c reductions of about 2.01\u20132.30%, depending on dose<\/li><li>Because it promotes insulin secretion in a glucose-dependent manner, the risk of hypoglycemia when used alone is low<\/li><li>The improvement is especially marked in patients with high blood sugar<\/li><\/ul><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\"><strong>5-3. Safety<\/strong><\/p><ul class=\"cv2-ul\"><li>The main side effects are gastrointestinal symptoms such as <strong>nausea, constipation and diarrhea<\/strong><\/li><li>Severe hypoglycemia and pancreatitis are rare<\/li><li>Research on the effects of long-term use on cardiovascular events is ongoing<\/li><\/ul><\/div><\/div>\n\n\n\n  <a href=\"https:\/\/www.hiro-clinic.or.jp\/diet\/manjaro-fukusayou-anzen\/\" class=\"blogcard\">\n    <div class=\"blogcard-content\">\n      <h3 class=\"blogcard-title\">\n        \u30de\u30f3\u30b8\u30e3\u30ed\u306e\u526f\u4f5c\u7528\uff5c\u7a2e\u985e\u30fb\u983b\u5ea6\u30fb\u5bfe\u51e6\u6cd5\u3092\u533b\u5e2b\u304c\u89e3\u8aac      <\/h3>\n      <small class=\"blogcard-excerpt\">\n        \u5148\u306b\u7d50\u8ad6\u5fd9\u3057\u3044\u65b9\u306f\u3053\u3053\u3060\u3051\u8aad\u3081\u3070OK\u30de\u30f3\u30b8\u30e3\u30ed\u306e\u526f\u4f5c\u7528\u306f\u5410\u304d\u6c17\u30fb\u4e0b\u75e2\u30fb\u4fbf\u79d8\u306a\u3069...\t  <\/small>\n    <\/div>\n  <\/a>\n\n  \n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Weight loss strategies using Mounjaro<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>To get the effects of Mounjaro safely, three foundations are essential: reviewing lifestyle habits, managing self-injections and regular follow-up.<\/strong><\/mark> Mounjaro has a weight loss effect even when used alone, but keeping the following points in mind allows you to use it more safely and effectively.<\/p>\n\n\n\n<ol class=\"cv2-sc cv2-sc--2\"><li><p class=\"cv2-sc__h\">Combine with lifestyle improvements<\/p><p>Continuing a nutritionally balanced diet and exercise therapy maximizes the weight loss effect<\/p><\/li><li><p class=\"cv2-sc__h\">Managing once-weekly self-injections<\/p><p>The dosing schedule is simple, improving long-term adherence<\/p><\/li><li><p class=\"cv2-sc__h\">Regular medical follow-up<\/p><p>Check blood sugar, weight and side effects regularly with your doctor<\/p><\/li><li><p class=\"cv2-sc__h\">Setting a target weight<\/p><p>It is important to set realistic and safe weight loss goals based on BMI and body fat percentage. Rapid weight loss can lead to feeling unwell or nutritional deficiencies. Because Mounjaro has a strong appetite-suppressing effect, it allows safe weight management while supporting a natural reduction in food intake.<\/p><\/li><li><p class=\"cv2-sc__h\">Dealing with side effects<\/p><p>If gastrointestinal symptoms appear, it is possible to continue by consulting your doctor about adjusting the dose and making changes to what you eat. Nausea and constipation may appear especially at the start, but in many cases they ease over time.<\/p><\/li><li><p class=\"cv2-sc__h\">Possibility of combination therapy<\/p><p>Mounjaro can be used together with other diabetes or obesity medications, but care is needed regarding drug interactions and the risk of hypoglycemia. Combined use is premised on being under a doctor&#8217;s guidance.<\/p><\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Comparative studies of Mounjaro and GLP-1 receptor agonists<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>In the SURPASS-2 trial, which directly compared Mounjaro with semaglutide, Mounjaro showed greater results in both HbA1c reduction and weight loss.<\/strong><\/mark> In recent years, Mounjaro has also shown significant weight loss effects in comparative trials with existing GLP-1 receptor agonists.<\/p>\n\n\n\n<div class=\"cv2-cards cv2-cards--3 cv2-cards--hd\"><div class=\"cv2-card\"><p class=\"cv2-card__h\">Weight loss rate<\/p><ul class=\"cv2-ul\"><li>Mounjaro group in the SURMOUNT-1 trial: average reduction of 15\u201321% over 72 weeks<\/li><li>Liraglutide group (SCALE trial): average reduction of 5\u201310%<\/li><\/ul><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\">Appetite suppression effect<\/p><p>Because Mounjaro acts on appetite regulation through both GIP and GLP-1 receptors, it has been reported to make it easier to self-regulate food intake<\/p><\/div><div class=\"cv2-card\"><p class=\"cv2-card__h\">Blood sugar improvement effect<\/p><p>In the SURPASS-2 trial, the HbA1c reduction in the Mounjaro groups (2.01\u20132.30%) exceeded the reduction in the semaglutide 1 mg group (1.86%)<\/p><\/div><\/div>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"640\" height=\"427\" src=\"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/25384793_s.webp\" alt=\"Scale\" class=\"wp-image-1157\" srcset=\"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/25384793_s.webp 640w, https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/25384793_s-300x200.webp 300w\" sizes=\"auto, (max-width: 640px) 100vw, 640px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Precautions when using Mounjaro<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>With Mounjaro, particular attention is needed to three points: it should not be used during pregnancy or breastfeeding, the risk of pancreatitis, and careful administration in patients with reduced kidney function.<\/strong><\/mark><\/p>\n\n\n\n<ol class=\"cv2-sc\"><li><p class=\"cv2-sc__h\">Use during pregnancy and breastfeeding<\/p><p>Its safety during pregnancy and breastfeeding has not been sufficiently established, so its use is not recommended.<\/p><\/li><li><p class=\"cv2-sc__h\">Risk of pancreatitis<\/p><p>Pancreatitis is a rare side effect reported for GLP-1 receptor agonists in general. If you have strong abdominal pain, nausea or similar symptoms, seek medical care immediately.<\/p><\/li><li><p class=\"cv2-sc__h\">Patients with reduced kidney function<\/p><p>If kidney function is reduced, dose adjustment and close monitoring are necessary.<\/p><\/li><\/ol>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Reasons to choose Mounjaro<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>Mounjaro can be a strong option from three perspectives: ease of continuing treatment, weight loss effect and blood sugar improvement.<\/strong><\/mark> Mounjaro is a better option than other GLP-1 receptor agonists in the following respects.<\/p>\n\n\n\n<ul class=\"cv2-ul cv2-ul--check cv2-ul--frame\"><li>Once-weekly dosing makes it easy to continue, with high treatment adherence<\/li><li>With the addition of GIP action, weight loss through appetite suppression has been clearly shown in clinical trials<\/li><li>It also has a strong blood sugar\u2013improving effect, with a low risk of hypoglycemia when used alone<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Because of these features, it is one option especially for patients with type 2 diabetes seeking obesity treatment and patients with a high BMI. Please note that in Japan, Mounjaro is approved only for the treatment of type 2 diabetes, and its use for weight loss is off-label use and self-pay treatment (the full cost is borne by the patient).<\/p>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Examples of use in actual clinical practice<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><mark><strong>In clinical practice, its use is considered in three patterns: patients with obesity with a BMI of 30 or more, patients with type 2 diabetes with inadequate blood sugar control, and patients for whom conventional drugs were not effective enough.<\/strong><\/mark> In clinical practice, Mounjaro is used effectively in cases such as the following.<\/p>\n\n\n\n<ol class=\"cv2-sc\"><li><p class=\"cv2-sc__h\">Patients with obesity with a BMI of 30 or more<\/p><p>Uses the appetite-suppressing effect to support a manageable reduction in food intake and weight loss<\/p><\/li><li><p class=\"cv2-sc__h\">Patients with type 2 diabetes whose blood sugar control is inadequate<\/p><p>Stabilizes blood sugar through promotion of insulin secretion and suppression of glucagon<\/p><\/li><li><p class=\"cv2-sc__h\">When weight loss with conventional drugs was insufficient<\/p><p>Makes use of the strength of GIP action to differentiate it from conventional drugs<\/p><\/li><\/ol>\n\n\n\n<div class=\"cv2-midcta\"><p class=\"cv2-midcta__t\">Would you like to ask a doctor whether Mounjaro could be an option for your condition?<\/p><div class=\"cv2-btns\"><a class=\"cv2-btn cv2-btn--coral\" href=\"https:\/\/mypage-online-reservation.hiro-clinic.or.jp\/register?department=diet\">Book a counseling session now<\/a><a class=\"cv2-btn cv2-btn--line\" href=\"https:\/\/www.hiro-clinic.or.jp\/diet\/line\/\">Free consultation on LINE<\/a><\/div><p class=\"cv2-midcta__d\" style=\"margin:12px 0 0!important\">*This is self-pay treatment. Effects and side effects vary from person to person.<\/p><\/div>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2--faq\" id=\"faq\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Here are answers to frequently asked questions about the differences between Mounjaro and other GLP-1 receptor agonists.<\/strong><\/p>\n\n\n\n<div class=\"cv2-faqs\"><details class=\"cv2-faq\" open><summary><span class=\"cv2-q\">Q<\/span>Is Mounjaro always more effective than semaglutide?<\/summary><div class=\"cv2-a\"><span class=\"cv2-aa\">A<\/span><div><p>In the SURPASS-2 trial in patients with type 2 diabetes, Mounjaro showed greater HbA1c reduction and weight loss than semaglutide 1 mg. However, effects vary from person to person, and the most suitable medication differs depending on constitution and medical history.<\/p><\/div><\/div><\/details><details class=\"cv2-faq\" open><summary><span class=\"cv2-q\">Q<\/span>What changes when a drug acts on both GIP and GLP-1?<\/summary><div class=\"cv2-a\"><span class=\"cv2-aa\">A<\/span><div><p>Compared with GLP-1-only drugs, clinical trials have reported that adding GIP action tends to strengthen appetite suppression and weight loss. However, the detailed mechanism of why GIP action produces this additional effect is still being researched.<\/p><\/div><\/div><\/details><details class=\"cv2-faq\" open><summary><span class=\"cv2-q\">Q<\/span>Should I choose Mounjaro or liraglutide (Saxenda)?<\/summary><div class=\"cv2-a\"><span class=\"cv2-aa\">A<\/span><div><p>They differ in dosing frequency (Mounjaro once weekly, liraglutide daily) and in the size of the weight loss effect. Which is appropriate depends on your daily routine, constitution and treatment goals, so it is important to decide after consulting your doctor.<\/p><\/div><\/div><\/details><details class=\"cv2-faq\" open><summary><span class=\"cv2-q\">Q<\/span>Are the side effects different from other GLP-1 receptor agonists?<\/summary><div class=\"cv2-a\"><span class=\"cv2-aa\">A<\/span><div><p>Gastrointestinal symptoms such as nausea, constipation and diarrhea are typical side effects reported for GLP-1 drugs in general, including Mounjaro. Although frequency and severity differ by drug, in all cases they tend to appear early in treatment and ease over time.<\/p><\/div><\/div><\/details><details class=\"cv2-faq\" open><summary><span class=\"cv2-q\">Q<\/span>Is Mounjaro covered by health insurance in Japan for weight loss?<\/summary><div class=\"cv2-a\"><span class=\"cv2-aa\">A<\/span><div><p>No. In Japan, Mounjaro is approved as a medication for type 2 diabetes, and its use for weight loss (obesity treatment) is off-label use. It is not covered by health insurance and is self-pay treatment (the full cost is borne by the patient).<\/p><\/div><\/div><\/details><\/div>\n\n\n\n<script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Mounjaro always more effective than semaglutide?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"In the SURPASS-2 trial in patients with type 2 diabetes, Mounjaro showed greater HbA1c reduction and weight loss than semaglutide 1 mg. However, effects vary from person to person, and the most suitable medication differs depending on constitution and medical history.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What changes when a drug acts on both GIP and GLP-1?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Compared with GLP-1-only drugs, clinical trials have reported that adding GIP action tends to strengthen appetite suppression and weight loss. However, the detailed mechanism of why GIP action produces this additional effect is still being researched.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Should I choose Mounjaro or liraglutide (Saxenda)?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"They differ in dosing frequency (Mounjaro once weekly, liraglutide daily) and in the size of the weight loss effect. Which is appropriate depends on your daily routine, constitution and treatment goals, so it is important to decide after consulting your doctor.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Are the side effects different from other GLP-1 receptor agonists?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Gastrointestinal symptoms such as nausea, constipation and diarrhea are typical side effects reported for GLP-1 drugs in general, including Mounjaro. Although frequency and severity differ by drug, in all cases they tend to appear early in treatment and ease over time.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Mounjaro covered by health insurance in Japan for weight loss?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"No. In Japan, Mounjaro is approved as a medication for type 2 diabetes, and its use for weight loss (obesity treatment) is off-label use. It is not covered by health insurance and is self-pay treatment (the full cost is borne by the patient).\"\n      }\n    }\n  ]\n}\n<\/script>\n\n\n\n<!--cv2-final-->\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>Summary<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mounjaro stands apart from existing GLP-1 receptor agonists in that it acts on two hormones, GIP and GLP-1.<\/strong> With once-weekly dosing, it also has a strong blood sugar\u2013improving effect and may be able to support obesity treatment and diabetes management at the same time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The difference from other GLP-1 receptor agonists lies in whether or not they have GIP action and the resulting size of the weight loss effect, for which evidence has been shown in clinical trials. It is important to continue treatment safely under a doctor&#8217;s supervision while combining it with appropriate lifestyle improvements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading cv2-h2\"><strong>References<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>All numerical data in this article are based on peer-reviewed clinical trial publications.<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). <em>N Engl J Med<\/em>. 2022;387:205-216.<br><\/li>\n\n\n\n<li>Fr\u00edas JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). <em>N Engl J Med<\/em>. 2021;385:503-515.<br><\/li>\n\n\n\n<li>Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). <em>N Engl J Med<\/em>. 2021;384:989-1002.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"mounjaro-safety-contact\">Who to contact if you have side effects | When to seek care<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>If any of the following symptoms occur, please contact us rather than waiting to see on your own.<\/strong> GIP\/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly gastrointestinal symptoms. Most are mild, but serious ones occur in rare cases.<\/p>\n\n\n\n<div class=\"cv2-tablewrap\"><figure class=\"wp-block-table\"><table><thead><tr><th>Symptom<\/th><th>Possible cause<\/th><th>What to do<\/th><\/tr><\/thead><tbody>\n<tr><td>Persistent nausea or vomiting<\/td><td>Gastrointestinal symptoms; the most common side effect<\/td><td>Contact us if you continue to be unable to keep fluids down<\/td><\/tr>\n<tr class=\"is-urgent\"><td><strong>Severe abdominal pain<\/strong> (pain that radiates to the back)<\/td><td><strong>Possible acute pancreatitis<\/strong><\/td><td>Stop the medication immediately and seek medical care<\/td><\/tr>\n<tr><td>Cold sweat, palpitations, intense hunger, feeling confused or drowsy<\/td><td><strong>Hypoglycemia<\/strong><\/td><td>Take sugar right away and contact us<\/td><\/tr>\n<tr class=\"is-urgent\"><td>Skin rash, difficulty breathing, swelling of the face or throat<\/td><td>Allergic reaction<\/td><td>Seek medical care immediately<\/td><\/tr>\n<\/tbody><\/table><\/figure><\/div>\n\n\n\n<div class=\"cv2-tel\"><a class=\"cv2-tel__btn\" href=\"tel:0120241929\"><span class=\"cv2-tel__s\">Contact: <\/span><span class=\"cv2-tel__num\">0120-241-929<\/span><span class=\"cv2-tel__h\"> (hours 9:00\u201318:00)<\/span><\/a><p class=\"cv2-tel__n\">If your symptoms are severe outside these hours, please go to a nearby emergency medical facility.<\/p><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Direct phone numbers for each clinic are listed on the <a href=\"\/diet\/clinic-info\/\">clinic information<\/a> page.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">References<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The information about medications in this article is based on the following official sources. For details on dosage and administration and side effects, always check the latest electronic package insert.<br>\n<a href=\"https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/2499422G1024_1\" target=\"_blank\" rel=\"noopener\">Pharmaceuticals and Medical Devices Agency (PMDA): &#8220;Mounjaro Subcutaneous Injection Ateos, electronic package insert&#8221; (Japanese)<\/a><br>\n<a href=\"https:\/\/www.info.pmda.go.jp\/downfiles\/guide\/ph\/530471_2499422G1024_1_00G.pdf\" target=\"_blank\" rel=\"noopener\">PMDA: &#8220;Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos&#8221; (PDF, Japanese)<\/a><br>\n<a href=\"https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/kenkou_iryou\/kenkou\/seikatsu\/index.html\" target=\"_blank\" rel=\"noopener\">Ministry of Health, Labour and Welfare: &#8220;Prevention of lifestyle-related diseases&#8221; (Japanese)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>When Mounjaro is used for purposes other than obesity disease, it is self-pay treatment and is not covered by public health insurance. Effects and side effects vary from person to person.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\" style=\"font-size:0.85em;color:#666;\">Medically reviewed by: Dr. Hiroko Oka (Chair, Fukubikai Medical Corporation \/ Certified Member, Japanese Society of Internal Medicine)<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Mounjaro differs in its mechanism of action from existing GLP-1 receptor agonists in that it acts on two types [&hellip;]<\/p>\n","protected":false},"author":49,"featured_media":1233,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[171],"tags":[37,14,172,157],"class_list":["post-16002","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-171","tag-37","tag-14","tag-172","tag-157"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>How Mounjaro works: dual GIP\/GLP-1 action | Hiro Clinic<\/title>\n<meta name=\"description\" content=\"Why does Mounjaro curb appetite? We explain its first-of-its-kind action on both GIP and GLP-1 receptors and how it differs from earlier GLP-1 drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How Mounjaro works: dual GIP\/GLP-1 action | Hiro Clinic\" \/>\n<meta property=\"og:description\" content=\"Why does Mounjaro curb appetite? We explain its first-of-its-kind action on both GIP and GLP-1 receptors and how it differs from earlier GLP-1 drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/\" \/>\n<meta property=\"og:site_name\" content=\"\u30d2\u30ed\u30af\u30ea\u30cb\u30c3\u30af\u533b\u7642\u30c0\u30a4\u30a8\u30c3\u30c8\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-24T02:16:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T07:27:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"fujitanaoki\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"fujitanaoki\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How Mounjaro works: dual GIP\/GLP-1 action | Hiro Clinic","description":"Why does Mounjaro curb appetite? We explain its first-of-its-kind action on both GIP and GLP-1 receptors and how it differs from earlier GLP-1 drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/","og_locale":"ja_JP","og_type":"article","og_title":"How Mounjaro works: dual GIP\/GLP-1 action | Hiro Clinic","og_description":"Why does Mounjaro curb appetite? We explain its first-of-its-kind action on both GIP and GLP-1 receptors and how it differs from earlier GLP-1 drugs.","og_url":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/","og_site_name":"\u30d2\u30ed\u30af\u30ea\u30cb\u30c3\u30af\u533b\u7642\u30c0\u30a4\u30a8\u30c3\u30c8","article_published_time":"2025-09-24T02:16:45+00:00","article_modified_time":"2026-11-17T07:27:14+00:00","og_image":[{"width":640,"height":427,"url":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp","type":"image\/webp"}],"author":"fujitanaoki","twitter_card":"summary_large_image","twitter_misc":{"Written by":"fujitanaoki","Est. reading time":"13\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#article","isPartOf":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/"},"author":{"name":"fujitanaoki","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/#\/schema\/person\/a28fded3d78d5f9df507e158668eb48f"},"headline":"How Mounjaro works | A doctor explains its dual action on GIP and GLP-1","datePublished":"2025-09-24T02:16:45+00:00","dateModified":"2026-11-17T07:27:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/"},"wordCount":2615,"commentCount":0,"image":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp","keywords":["\u30c0\u30a4\u30a8\u30c3\u30c8","\u30de\u30f3\u30b8\u30e3\u30ed","\u30de\u30f3\u30b8\u30e3\u30ed\u6ce8\u5c04","\u533b\u7642\u30c0\u30a4\u30a8\u30c3\u30c8"],"articleSection":["\u30de\u30f3\u30b8\u30e3\u30ed\u6ce8\u5c04"],"inLanguage":"ja","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/","url":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/","name":"How Mounjaro works: dual GIP\/GLP-1 action | Hiro Clinic","isPartOf":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#primaryimage"},"image":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp","datePublished":"2025-09-24T02:16:45+00:00","dateModified":"2026-11-17T07:27:14+00:00","author":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/#\/schema\/person\/a28fded3d78d5f9df507e158668eb48f"},"description":"Why does Mounjaro curb appetite? We explain its first-of-its-kind action on both GIP and GLP-1 receptors and how it differs from earlier GLP-1 drugs.","breadcrumb":{"@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#primaryimage","url":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp","contentUrl":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-content\/uploads\/2025\/09\/3448838_s.webp","width":640,"height":427,"caption":"\u533b\u8005"},{"@type":"BreadcrumbList","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/en\/manjaro-glp1-sakyou-sa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hiro-clinic.or.jp\/diet\/"},{"@type":"ListItem","position":2,"name":"How Mounjaro works | A doctor explains its dual action on GIP and GLP-1"}]},{"@type":"WebSite","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/#website","url":"https:\/\/www.hiro-clinic.or.jp\/diet\/","name":"\u30d2\u30ed\u30af\u30ea\u30cb\u30c3\u30af\u533b\u7642\u30c0\u30a4\u30a8\u30c3\u30c8","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hiro-clinic.or.jp\/diet\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/www.hiro-clinic.or.jp\/diet\/#\/schema\/person\/a28fded3d78d5f9df507e158668eb48f","name":"fujitanaoki","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/secure.gravatar.com\/avatar\/76192f07e3cf18f67455110082d9b0fc56c218fb3f582c3a8de3817cb7059af9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/76192f07e3cf18f67455110082d9b0fc56c218fb3f582c3a8de3817cb7059af9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/76192f07e3cf18f67455110082d9b0fc56c218fb3f582c3a8de3817cb7059af9?s=96&d=mm&r=g","caption":"fujitanaoki"},"url":"https:\/\/www.hiro-clinic.or.jp\/diet\/author\/fujitanaoki\/"}]}},"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/posts\/16002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/users\/49"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/comments?post=16002"}],"version-history":[{"count":1,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/posts\/16002\/revisions"}],"predecessor-version":[{"id":17052,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/posts\/16002\/revisions\/17052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/media\/1233"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/media?parent=16002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/categories?post=16002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/diet\/wp-json\/wp\/v2\/tags?post=16002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}